RGEN
Repligen Corporation
NASDAQ: RGEN · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$184.69
+5.06% today
Updated 2026-10-28
Market cap
$11.14B
P/E ratio
250.60
P/S ratio
14.19x
EPS (TTM)
$0.70
Dividend yield
—
52W range
$101 – $199
Volume
1.2M
Repligen Corporation (RGEN) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$184.69
12-Month target
$40.25
2030 Target
—
Intrinsic (DCF)
$141.32
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.7B | $0.8B | $0.6B | $0.6B | $0.7B | $0.8B | $1.0B | $1.1B | $1.3B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 15.05% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 5.29%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.